Avadel Pharmaceuticals (AVDL) announced the publication of combined findings from a social media analysis and a survey of people with narcolepsy taking twice-nightly sodium oxybate. Results showed that these individuals report inconsistent adherence to prescribed dosing, which can lead to negative consequences in their lives. The recommended dosing for twice-nightly sodium oxybates is a first dose at bedtime and a second dose administered 2.5 to 4 hours later. The paper, titled “Understanding the Patient Experience With Twice-Nightly Sodium Oxybate Therapy for Narcolepsy: A Social Listening Experiment,” was published in Brain Sciences.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals price target lowered to $25 from $27 at H.C. Wainwright
- Avadel Pharmaceuticals Reports Strong Growth with LUMRYZ
- Avadel Pharmaceuticals reports Q3 EPS (3c), consensus (5c)
- AVDL Upcoming Earnings Report: What to Expect?
- Court ruling removes ‘last binary risk’ for Avadel, says H.C. Wainwright